Caixin
Mar 12, 2022 04:00 PM
WEEKLY MUST-READ

Weekly Must-Read: China Meheco Confirms Pfizer Talks on Selling Paxlovid in China

Pfizer’s Covid-19 pill Paxlovid lowered hospitalization and death rates by 89% in patients who took it within five days of the onset of illness.
Pfizer’s Covid-19 pill Paxlovid lowered hospitalization and death rates by 89% in patients who took it within five days of the onset of illness.

The Caixin Must-Read newsletter brings you the best of our coverage over the past week, handpicked by our editors.

# Business #

China Meheco Links Up With Pfizer to Market Covid Pill

State-owned drugmaker signs 2022 supply contract to commercialize Paxlovid as the first foreign treatment approved in China

China Meheco Confirms Pfizer Talks on Selling Paxlovid in China

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription